Trial Profile
A Phase II Study of MK-3475 (Pembrolizumab) (NSC #776864) + Epacadostat (NSC #766086) in Recurrent Clear Cell Carcinoma of the Ovary
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 26 Oct 2023
Price :
$35
*
At a glance
- Drugs Epacadostat (Primary) ; Pembrolizumab (Primary)
- Indications Carcinoma; Ovarian cancer
- Focus Therapeutic Use
- 26 Sep 2023 Planned End Date changed from 9 Mar 2024 to 22 Sep 2024.
- 29 Mar 2023 Planned End Date changed from 9 Mar 2023 to 9 Mar 2024.
- 03 Feb 2021 Status changed from active, no longer recruiting to discontinued (Due to External information).